Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer

A phase II trial

F. Boccardo, M. Pace, D. Guarneri, L. Canobbio, A. Curotto, G. Martorana

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background. A Phase II study with carboplatin, methotrexate, and vinblastine (CAMV) was conducted with patients who had advanced urothelial cancer to investigate the activity and toxicity of carboplatin when used in combination chemotherapy. Methods. Thirty-six patients with advanced urothelial cancer were treated with carboplatin 300 mg/m2 (day 1), methotrexate 40 mg/m2 (days 1 and 8) and vinblastine 4 mg/m2 (days 1 and 8) every 4 weeks. Characteristics of the patients were as follows: men:women, 32:4; median age, 65 years (range, 42-76 years); and median Eastern Cooperative Oncology Group performance status, 0 (range, 0-2). Thirty-six patients were evaluable for toxicity and 33 for response. Results. Objective responses (OR) were achieved in 13 patients: 2 were complete responses (CR) (6%) and 11 were partial responses (33.4%). Median duration of OR was 7 months (range, 3-27 months). Median duration of CR was 10 months (range, 4- 27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months). Patients with a pretreatment creatinine clearance greater than or equal to 50 ml/minute showed a higher response rate: 48% OR and 10% CR. Toxicity was evaluated (World Health Organization criteria) on 164 cycles and was generally mild. Conclusion. CAMV is an active and safe regimen in patients with advanced urothelial cancer, even in those with impaired renal function. It is recommended that future studies with this regimen be performed with pharmacokinetic modulation of carboplatin to improve the drug's tolerability and therapeutic activity.

Original languageEnglish
Pages (from-to)1932-1936
Number of pages5
JournalCancer
Volume73
Issue number7
Publication statusPublished - 1994

Fingerprint

Vinblastine
Carboplatin
Methotrexate
Neoplasms
Therapeutics
Combination Drug Therapy
Creatinine
Pharmacokinetics
Kidney
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Boccardo, F., Pace, M., Guarneri, D., Canobbio, L., Curotto, A., & Martorana, G. (1994). Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer: A phase II trial. Cancer, 73(7), 1932-1936.

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer : A phase II trial. / Boccardo, F.; Pace, M.; Guarneri, D.; Canobbio, L.; Curotto, A.; Martorana, G.

In: Cancer, Vol. 73, No. 7, 1994, p. 1932-1936.

Research output: Contribution to journalArticle

Boccardo, F, Pace, M, Guarneri, D, Canobbio, L, Curotto, A & Martorana, G 1994, 'Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer: A phase II trial', Cancer, vol. 73, no. 7, pp. 1932-1936.
Boccardo, F. ; Pace, M. ; Guarneri, D. ; Canobbio, L. ; Curotto, A. ; Martorana, G. / Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer : A phase II trial. In: Cancer. 1994 ; Vol. 73, No. 7. pp. 1932-1936.
@article{89c28dd92e9446b4b604b96ad1df7308,
title = "Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer: A phase II trial",
abstract = "Background. A Phase II study with carboplatin, methotrexate, and vinblastine (CAMV) was conducted with patients who had advanced urothelial cancer to investigate the activity and toxicity of carboplatin when used in combination chemotherapy. Methods. Thirty-six patients with advanced urothelial cancer were treated with carboplatin 300 mg/m2 (day 1), methotrexate 40 mg/m2 (days 1 and 8) and vinblastine 4 mg/m2 (days 1 and 8) every 4 weeks. Characteristics of the patients were as follows: men:women, 32:4; median age, 65 years (range, 42-76 years); and median Eastern Cooperative Oncology Group performance status, 0 (range, 0-2). Thirty-six patients were evaluable for toxicity and 33 for response. Results. Objective responses (OR) were achieved in 13 patients: 2 were complete responses (CR) (6{\%}) and 11 were partial responses (33.4{\%}). Median duration of OR was 7 months (range, 3-27 months). Median duration of CR was 10 months (range, 4- 27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months). Patients with a pretreatment creatinine clearance greater than or equal to 50 ml/minute showed a higher response rate: 48{\%} OR and 10{\%} CR. Toxicity was evaluated (World Health Organization criteria) on 164 cycles and was generally mild. Conclusion. CAMV is an active and safe regimen in patients with advanced urothelial cancer, even in those with impaired renal function. It is recommended that future studies with this regimen be performed with pharmacokinetic modulation of carboplatin to improve the drug's tolerability and therapeutic activity.",
author = "F. Boccardo and M. Pace and D. Guarneri and L. Canobbio and A. Curotto and G. Martorana",
year = "1994",
language = "English",
volume = "73",
pages = "1932--1936",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer

T2 - A phase II trial

AU - Boccardo, F.

AU - Pace, M.

AU - Guarneri, D.

AU - Canobbio, L.

AU - Curotto, A.

AU - Martorana, G.

PY - 1994

Y1 - 1994

N2 - Background. A Phase II study with carboplatin, methotrexate, and vinblastine (CAMV) was conducted with patients who had advanced urothelial cancer to investigate the activity and toxicity of carboplatin when used in combination chemotherapy. Methods. Thirty-six patients with advanced urothelial cancer were treated with carboplatin 300 mg/m2 (day 1), methotrexate 40 mg/m2 (days 1 and 8) and vinblastine 4 mg/m2 (days 1 and 8) every 4 weeks. Characteristics of the patients were as follows: men:women, 32:4; median age, 65 years (range, 42-76 years); and median Eastern Cooperative Oncology Group performance status, 0 (range, 0-2). Thirty-six patients were evaluable for toxicity and 33 for response. Results. Objective responses (OR) were achieved in 13 patients: 2 were complete responses (CR) (6%) and 11 were partial responses (33.4%). Median duration of OR was 7 months (range, 3-27 months). Median duration of CR was 10 months (range, 4- 27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months). Patients with a pretreatment creatinine clearance greater than or equal to 50 ml/minute showed a higher response rate: 48% OR and 10% CR. Toxicity was evaluated (World Health Organization criteria) on 164 cycles and was generally mild. Conclusion. CAMV is an active and safe regimen in patients with advanced urothelial cancer, even in those with impaired renal function. It is recommended that future studies with this regimen be performed with pharmacokinetic modulation of carboplatin to improve the drug's tolerability and therapeutic activity.

AB - Background. A Phase II study with carboplatin, methotrexate, and vinblastine (CAMV) was conducted with patients who had advanced urothelial cancer to investigate the activity and toxicity of carboplatin when used in combination chemotherapy. Methods. Thirty-six patients with advanced urothelial cancer were treated with carboplatin 300 mg/m2 (day 1), methotrexate 40 mg/m2 (days 1 and 8) and vinblastine 4 mg/m2 (days 1 and 8) every 4 weeks. Characteristics of the patients were as follows: men:women, 32:4; median age, 65 years (range, 42-76 years); and median Eastern Cooperative Oncology Group performance status, 0 (range, 0-2). Thirty-six patients were evaluable for toxicity and 33 for response. Results. Objective responses (OR) were achieved in 13 patients: 2 were complete responses (CR) (6%) and 11 were partial responses (33.4%). Median duration of OR was 7 months (range, 3-27 months). Median duration of CR was 10 months (range, 4- 27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months). Patients with a pretreatment creatinine clearance greater than or equal to 50 ml/minute showed a higher response rate: 48% OR and 10% CR. Toxicity was evaluated (World Health Organization criteria) on 164 cycles and was generally mild. Conclusion. CAMV is an active and safe regimen in patients with advanced urothelial cancer, even in those with impaired renal function. It is recommended that future studies with this regimen be performed with pharmacokinetic modulation of carboplatin to improve the drug's tolerability and therapeutic activity.

UR - http://www.scopus.com/inward/record.url?scp=0028219304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028219304&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 1932

EP - 1936

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -